Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSante wins FDA nod for testosterone gel
The product was initially developed by BioSante and latter licensed to Teva for late stage clinical development, regulatory and marketing activities. BioSante is expected to receive royalties and
The product was initially developed by BioSante and latter licensed to Teva for late stage clinical development, regulatory and marketing activities. BioSante is expected to receive royalties and
The study finds selective pharmacological inhibition of specific arms of the ß2AR signaling network to correlate the differential contribution of signaling events to specific components of the cell
The assay aids in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies The
The patent number 8,114,874 was entitled, Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors. The new patent covers both the compound itself and its pharmaceutical compositions. Additional patent
Under the agreement, Health Management’s 66 hospitals in 15 states can upgrade to the latest version of McKesson’s AcuDose-Rx medication dispensing system to improve nursing workflow and optimize
Supera Farma is a Brazilian pharmaceutical company co-owned by Cristalia and Eurofarma. Merck will own 51% of the JV, managed by a joint board and leadership team, and
The European Commission approved tafamidis (the trade name in the European Union is VYNDAQEL) in November 2011, the company said. The FDA has granted the tafamidis NDA a
The LabNexus laboratory outreach solution is easy to navigate, secure, and accessible, enabling physicians to provide premium healthcare to their patients from anywhere they have an internet connection.
The comparative study will evaluate the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP. The study reported that Factor VIIa-CTP showed superior
The FDA request reflects a 17% increase over the FDA enacted budget for FY 2012. The FY 2013 request covers the period from 1 October 2012 through 30